| 产品描述: | Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) |
| 靶点: |
FGFR1:3.9 nM (IC50);FGFR2:1.3 nM (IC50);FGFR3:1.6 nM (IC50);FGFR4:8.3 nM (IC50);wild-type FGFR2:0.3 nM (IC50);FGFR2 V5651:1-3 nM (IC50);FGFR2 N550H:3.6 nM (IC50);FGFR2 E566G:2.4 nM (IC50);FGFR |
| 体外研究: |
Futibatinib (TAS-120) covalently binds to a highly conserved P-loop cysteine residue in the ATP pocket of FGFR |
| 体内研究: |
Futibatinib (TAS-120) (3, 30, 100 mg/kg/day, p.o.) exerts an anti-tumor effect in mice. Futibatinib (TAS-120) shows anti-tumor effect by administering at moderate intervals, such as intermittent administration of every other day dosing and 2 times/week, and reducing the sustained elevation and weight suppression blood phosphorus level, and take a antitumor effective as daily administration |
| 参考文献: |
1. Goyal L, et al. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 Aug;9(8):1064-1079. 2. Kalyukina M, et al. TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure. ChemMedChem. 2019 Feb 19;14(4):494-500. 3. Lamarca A, et al. Molecular targeted therapies: Ready for 'prime time' in biliary tract cancer [published online ahead of print, 2020 Mar 12]. J Hepatol. 2020;S0168-8278(20)30165-3. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.39 ml |
11.949 ml |
23.898 ml |
| 5 mM |
0.478 ml |
2.39 ml |
4.78 ml |
| 10 mM |
0.239 ml |
1.195 ml |
2.39 ml |
| 50 mM |
0.048 ml |
0.239 ml |
0.478 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |